• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Advanced Functional Materials >A Versatile Prodrug Strategy to In Situ Encapsulate Drugs in MOF Nanocarriers: A Case of Cytarabine-IR820 Prodrug Encapsulated ZIF-8 toward Chemo-Photothermal Therapy
【24h】

A Versatile Prodrug Strategy to In Situ Encapsulate Drugs in MOF Nanocarriers: A Case of Cytarabine-IR820 Prodrug Encapsulated ZIF-8 toward Chemo-Photothermal Therapy

机译：MOF纳米载体中原位封装药物的多功能前药策略：阿糖胞苷IR820前体药物封装的ZIF-8对化学光热疗法的案例

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Zeolitic imidazolate framework-8 (ZIF-8) is an attractive metal organic framework (MOF) in drug delivery. Strong interaction between drugs and ZIF-8 is essential for high drug loadings through in situ construction of MOFs. However, only limited drugs with unique functional groups (-COOH, -SO3H, et al.) can interact with ZIF-8 and be encapsulated satisfactorily so far. Drugs without these functional groups are difficult to be loaded due to the lack of strong interaction. Herein a versatile prodrug strategy is proposed to solve the problems encountered by MOFs. Cytarabine (Ara) is chosen as a model drug since it cannot be loaded in ZIF-8 satisfactorily by itself. New indocyanine green (IR820) is utilized to bond with Ara for the formation of prodrug (Ara-IR820) and endows the prodrug with fluorescence imaging-guided chemo-photothermal therapy, in which sulfonic groups strengthen the interaction between prodrug and ZIF-8. This prodrug loaded ZIF-8 is further functionalized with hyaluronic acid (HA) to result in active-targeting HA/Ara-IR820@ZIF-8 nanoparticles. The in vitro and in vivo results demonstrate its excellent visual cancer therapy with tumor-targeted and pH-responsive release behavior. This design offers a new concept to solve the drug loading problem of MOFs, exhibiting a flexible strategy to expand the biomedical applications of MOFs.
机译：沸石咪唑烷基骨架8（ZIF-8）是药物递送中有吸引力的金属有机骨架（MOF）。通过MOF的原位构建，药物与ZIF-8之间的强相互作用对于高药物负载至关重要。但是，只有具有独特功能基团的有限药物（-COOH，-SO3H等）才能与ZIF-8相互作用，并可以令人满意地进行包囊。没有这些官能团的药物由于缺乏强相互作用而难以装载。本文提出了一种通用的前药策略来解决MOF所遇到的问题。选择阿糖胞苷（Ara）作为模型药物，因为它本身不能令人满意地装载在ZIF-8中。新的吲哚菁绿（IR820）用于与Ara结合形成前药（Ara-IR820），并使前药具有荧光成像引导的化学光热疗法，其中磺酸基团增强了前药与ZIF-8之间的相互作用。将该负载前药的ZIF-8进一步用透明质酸（HA）进行功能化，以产生靶向活性的HA / Ara-IR820 @ ZIF-8纳米粒子。体外和体内结果证明了其出色的视觉癌症疗法，具有靶向肿瘤和pH响应释放的特性。该设计提供了解决MOFs载药问题的新概念，展示了扩展MOFs在生物医学领域的灵活策略。

著录项

  • 来源
    《Advanced Functional Materials》 |2018年第35期|1802830.1-1802830.10|共10页
  • 作者

    Zhang Huiyuan; Li Qian; Liu Ruiling; Zhang Xinke; Li Zhonghao; Luan Yuxia;

  • 作者单位

    Shandong Univ, Sch Pharmaceut Sci, 44 West Wenhua Rd, Jinan 250012, Shandong, Peoples R China;

    Shandong Univ, Sch Pharmaceut Sci, 44 West Wenhua Rd, Jinan 250012, Shandong, Peoples R China;

    Shandong Univ, Sch Pharmaceut Sci, 44 West Wenhua Rd, Jinan 250012, Shandong, Peoples R China;

    Shandong Univ, Sch Pharmaceut Sci, 44 West Wenhua Rd, Jinan 250012, Shandong, Peoples R China;

    Shandong Univ, Key Lab Colloid & Interface Chem, Minist Educ, Jinan 250100, Shandong, Peoples R China;

    Shandong Univ, Sch Pharmaceut Sci, 44 West Wenhua Rd, Jinan 250012, Shandong, Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    chemotherapy; drug delivery; MOFs; photothermal therapy; ZIF-8;

    机译：化疗;药物输送;MOFs;光热疗法;ZIF-8;

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号